GlassScriptPhysician profile
Tara Delacruz
NPI 1285363846
$2,867.63
in general payments reported to CMS, 2019-2025
18 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $266 · 2024: $1,158 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846 · Education: $21.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.83 |
| Education | $21.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $663.81 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $544.65 | 2023-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $392.02 | 2023-2025 | Jynarque |
| Sobi, INC | $286.77 | 2023-2025 | |
| Janssen Biotech, INC. | $173.32 | 2024-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $114.89 | 2023-2025 | Saphnelo, Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $111.32 | 2025 | Benlysta |
| Alnylam Pharmaceuticals INC. | $101.90 | 2025 | Givlaari, Oxlumo |
| Calliditas Therapeutics US INC. | $100.24 | 2024-2025 | Tarpeyo |
| Amgen INC. | $77.00 | 2024 | Tavneos |
| Fresenius Kabi USA, LLC | $62.62 | 2024-2025 | Idacio |
| Novo Nordisk INC | $52.84 | 2024 | Rivfloza |
| Ucb, INC. | $44.95 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.08 | 2025 | |
| Abbvie INC. | $29.04 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $26.54 | 2023 | |
| Vifor Pharma, INC. | $25.84 | 2025 | Veltassa |
| Celltrion USA INC. | $21.80 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Delacruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.